

Viamet to Provide Update on Novel Antifungal Programs at ECCMID 2015

April 24, 2015 09:20 AM Eastern Daylight Time - RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today announced that data related to its novel antifungal programs will be presented at the European Congress for Clinical Microbiology and Infectious Diseases Conference in Copenhagen, April 25 – 28, 2015.

Clinical and preclinical data will be presented for VT-1161, an oral agent currently in Phase 2b studies for the treatment of onychomycosis and recurrent vulvovaginal candidiasis:

- Poster [PO228] titled "Efficacy and Safety of Oral VT-1161, a Novel Inhibitor of Fungal CYP51, in a Randomized Phase 2a Study in Patients with Acute Vulvovaginal Candidiasis," by Brand et al.
- Poster [PO1274] titled "High In Vitro Potency of the Clinical Investigational Agent VT-1161 Against Clinical Isolates of Candida Spp.," by Long et al.
- Oral poster [EPO14] titled "VT-1161 Protects Immunosuppressed Mice from Rhizopus Oryzae Infection," by Gebremarian et al.

In addition, preclinical data will be presented for VT-1129, an oral agent currently undergoing IND-enabling studies, that the Company intends to develop for the treatment of cryptococcal meningitis and other life-threatening fungal infections:

- Poster [PO232] titled "The Novel Fungal CYP51 Inhibitor VT-1129 Demonstrates Potent In Vivo Activity Against Cryptococcal Meningitis with a Loading/Maintenance Dosing Regimen," by Wiederhold et al.

Robert Schotzinger, MD, PhD, CEO of Viamet commented, "We are pleased to present these exciting data on our broad pipeline of novel antifungal agents, including VT-1161 and VT-1129. These compounds, and others in our pipeline, are highly potent and were specifically designed to avoid the safety issues that limit currently marketed antifungal agents. We believe that Viamet has the broadest and most robust portfolio of novel antifungal agents in the industry today."

The presentations will be available on the Company's website following presentation at the conference.

About Onychomycosis

Onychomycosis is a fungal infection that involves the nail matrix, nail bed, and nail plate. Onychomycosis can cause discoloration, thickening and splitting of the nail, as well as separation of the nail plate from the nail bed. The condition may result in pain when walking, thereby limiting ambulation. The abnormal appearance of the infected nails and the perception that there is an active and contagious infection is a significant concern for many patients. An estimated 32 million individuals in the United States suffer from this condition.

About Recurrent Vulvovaginal Candidiasis (RVVC)

RVVC is commonly defined as the occurrence of three or more acute vulvovaginal infections within a 12-month period. The infection involves the vaginal mucosa as well as the surrounding areas. RVVC can be a source of significant discomfort and leads to loss of work time as well as a significant negative impact on quality of life. There are currently no approved agents in the United States for the treatment of RVVC, which afflicts between 5% to 8% of women of child-bearing age in the United States.

About Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening fungal infection of the brain and the spinal cord. This infection occurs most often in patients with compromised immune systems, including patients with HIV, transplant recipients and oncology patients. Current treatment is very poorly tolerated and includes amphotericin B and flucytosine administered for two or more weeks, followed by chronic therapy with fluconazole for months or even years. Despite best available care, the mortality rate among patients with cryptococcal meningitis in the United States remains approximately 20%.

About Viamet (www.viamet.com)

Viamet is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on a proprietary metalloenzyme medicinal chemistry platform, the Metallophile Technology®. The Company is using this platform to design drugs that are expected to have greater selectivity and safety as well as improved potency compared to currently available therapeutics. The Company's initial product candidates include a portfolio of highly potent and selective novel antifungal agents.

Contact:

Richard Katz, M.D., Chief Business and Financial Officer Viamet Pharmaceuticals, Inc.

4505 Emperor Boulevard, Suite 300
Durham, North Carolina, USA 27703
Telephone: +919.467.8539 ext. 316

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business and VT-1161, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.